NeuroNEXT News

NIH soliciting for Pain Research Centers: Applications due June 3rd!

External Source:

NIH is soliciting for Pain Research Centers to join a clinical trial network. NIH has mounted a major effort to improve pain management as a part of its response to the opioid crisis in America. One cornerstone of that effort is an phase 2 clinical trial network to test new, non-addictive pain therapies in well-phenotyped patients. This is part of a public-private partnership with academia, pharmaceutical companies, biotechnology and device companies.

NN102 Dataset Available from NINDS Repository

External Source:

NINDS Archived Clinical Research Datasets

The dataset from the NN102 SPRINT-MS project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.

Dr. Robert Fox Receives Sones Innovation Award 2019

External Source:

Cleveland Clinic YouTube Channel

Dr. Robert Fox, PI of the NN102 SPRINT-MS study was the 2019 recipient of Cleveland Clinic's Sones Innovation Award for the advances in progressive multiple sclerosis made by the NN102 study. This award recognizes advances in innovation in the service of improved patient care. Congratulations to Dr. Fox and the NN102 SPRINT-MS team!

CTMC 2019 Application due February 28, 2019

Applications for the NINDS-funded Clinical Trials Methodology Course (CTMC) 2019 are due February 28, 2019 at midnight. Application forms and additional details are available at http://neurotrials.training. Early applications may be considered for early acceptance.

NN104 Primary Endpoint Manuscript Published

External Source:

Annals of Neurology

The NN104 RHAPSODY primary manuscript has been published in the January 2019 print issue of Annals of Neurology. As the abstract notes, this trial was important for three reasons:

NN101 Recruitment and Retention Highlighted by Cure SMA

External Source:

Cure SMA Provides Funding and Recruitment for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

NN101 SMA was recently featured in the Cure SMA newsletter, highlighting the recently-published Recruitment & Retention paper.

Dr. Merit Cudkowicz interviewed on 60 Minutes

External Source:

CBS News' 60 Minutes

Dr. Merit Cudkowicz, Principal Investigator of the NeuroNEXT CCC, was interviewed on CBS News' 60 Minutes on a feature about NFL star Tim Green coping with ALS. Her appearance begins at the 6:15 mark, and she discusses Mr. Green's prognosis and treatment.

NeuroNEXT Annual Meeting Slides Available

The slide presentation from the 2018 NeuroNEXT Annual Meeting in Boston, MA October 18-19 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!

NN101 Dataset Available from NINDS Repository

The dataset from the NN101 SMA project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.

NINDS Issues Press Release on NN102 SPRINT-MS Publication

External Source:

NINDS Press Release

NINDS has issued a press release regarding the publication of the NN102 SPRINT-MS study results in the New England Journal of Medicine. The press release quotes NINDS Director Walter J. Kroshetz, MD, saying the NN102 SPRINT-MS findings "provide a glimmer of hope for people with a form of nultiple sclerosis that causes long-term disability but does not have many treatment options."

NN102 Primary Results published in New England Journal of Medicine

External Source:

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.

NINDS Renews NeuroNEXT!

External Source:

NIH renews NeuroNEXT for neurological clinical research

The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding.

NeuroNEXT at the University of Iowa

The University of Iowa highlighted NeuroNEXT achievements in two campus publications: Iowa Now provides an overview of the ways the Network is accelerating the clinical trials process, and The Daily Iowan focuses on the ways NeuroNEXT is bringing together clinical sites and coordinating centers to advance neurological trials.

Clinical Trials Methodology Course 2018 Webinar Series

The Clinical Trials Methodology Course (CTMC) has begun their 2018 Webinar Series. These webinars are open to all. The course focues on the desing of early stage clinical trials for investigators focused on neurological illness and injury. The full scheduled may be viewed online: https://siren.network/training/ctmc/ctmc-webinars.

Neuro Central Podcast with Dr. Robert Fox, NN102 SPRINT-MS

External Source:

NCTalks with Robert Fox: current landscape and potential treatment regimens for ibudilast in MS

Neuro Central Podcast NC Talks featured an interview with Dr. Robert Fox, PPI of the NN102 SPRINT-MS study. Dr. Fox discussed trial results with the podcasters at the American Academy of Neurlogy's 70th Annual Meeting in Los Angeles, CA.

NeuroNEXT events at AAN 2018

The American Academy of Neurology (AAN) Annual Meeting will begin April 21 in Los Angeles, CA. The following NeuroNEXT events and presentations will take place:

NeuroNEXT represented at ASENT 2018 Annual Meeting

Network successes and the five-year renewal application were presented at the 2018 Annual Meeting of the American Society for Experimental Neurotherapeutics poster session.

NN104 RHAPSODY Results Featured in ISC 2018 newsletter and ASA blog post

External Source:

Blogging Stroke, Friday, January 26, 2018

Final results from the NN104 RHAPSODY trial, which were presented at the International Stroke Conference (ISC) 2018 as a closing event, were subsequently featured in ISC's Science News as Featured Science and on the American Stroke Association blog "Blogging Stroke."

NN104 RHAPSODY Coverage in the San Diego Union-Tribune

External Source:

San Diego Union Tribune, February 21, 2018

Results of the NN104 study were covered in the San Diego Union-Tribune. The article details the development of 3K3A-APC, the study drug, originally developed by The Scripps Research Institute in La Jolla, CA.

FDA guidance documents of interest to NeuroNEXT

The FDA released several guidance documents in February, 2018, three of which fall under the NeuroNEXT umbrella: ALS,

You are here

NeuroNEXT News